MimiVax is pioneering the development of SurVaxM, a novel immunotherapeutic vaccine designed to target survivin, a protein that is prevalent in 95% of glioblastomas and various other cancers. This patented peptide mimic vaccine works by training the immune system to recognize survivin-expressing cancer cells as foreign entities, thereby stimulating an immune response aimed at controlling tumor growth and preventing recurrence. SurVaxM is administered via subcutaneous injection and has shown promising results in clinical trials, demonstrating safety and tolerability in patients with newly diagnosed glioblastoma and recurrent malignant glioma. The vaccine's potential extends beyond brain cancer, as survivin is also found in multiple myeloma, melanoma, and other malignancies, suggesting a broad applicability for SurVaxM across various cancer types.

In addition to its focus on glioblastoma, MimiVax is actively exploring the use of SurVaxM in combination with other therapies, such as lenalidomide for multiple myeloma, and is conducting trials for neuroendocrine tumors. The company has received significant recognition from the U.S. Food and Drug Administration (FDA), including Fast Track Designation and Supplemental Orphan Drug Designation for SurVaxM, which enhances its development pathway and market exclusivity. With ongoing clinical trials and a robust patent portfolio, MimiVax is committed to advancing innovative immunotherapies that aim to improve survival rates and quality of life for cancer patients.

United States

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates  MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.   SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. 

MimiVax

Company Details